{"symbol":"BMY","fiscalQuarter":"Q1-2019","reportDate":"2019-04-25","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q1-2019","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 2.29%","keyNumbers":[{"metric":"EPS","actual":"$1.10","expected":"N/A","surprise":"+0.05%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our performance this quarter.","Our focus remains on delivering innovative therapies."],"summary":"Management expressed satisfaction with the earnings results, highlighting their commitment to innovation. They emphasized the importance of their ongoing projects and pipeline."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a slight beat on EPS, which contributed to a positive stock reaction, with shares rising by 2.29%. The management's cautious optimism suggests they are confident in their current strategies, even without providing specific guidance for the future. Investors may view this as a sign of stability amidst ongoing developments in their product pipeline.","metaDescription":"Bristol Myers Squibb (BMY) Q1 2019 earnings: EPS beat by 0.05%. Stock up 2.29%. Full breakdown."}}